CClinicalTrials.gg
Sign In
Not yet recruitingNCT07718373Updated Aug 10, 2026

Early Postoperative L-arginine and Acute Kidney Injury After Cardiac Surgery

An observational study in Acute Kidney Injury, sponsored by Xijing Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Xijing Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Study summary

Acute kidney injury (AKI) is common after cardiac surgery, yet effective protective strategies remain limited. L-arginine is the substrate for endogenous nitric oxide (NO) synthesis and may improve renal perfusion and endothelial function. investigators emulated a target trial to evaluate whether early perioperative L-arginine was associated with a lower risk of AKI after cardiac surgery.

02

Conditions studied

  • Acute Kidney Injury

Browse trials for

03

In context

Acute Kidney Injury

1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 150 across 773 observational studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Xijing Hospital is the lead sponsor of 465 studies on the registry; 157 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adults admitted to the ICU after CPB-assisted cardiac surgery

Inclusion criteria

·adults admitted to the ICU after CPB-assisted cardiac surgery

Exclusion criteria

Exclusion Criteria:

  • congenital heart disease,
  • surgery requiring deep hypothermic circulatory arrest,
  • a preoperative baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²,
  • AKI already present prior to ICU admission
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • L-arginine

    Initiation of L-arginine within 3 postoperative days

    Drug: L-arginine

  • No L-arginine

    No L-arginine therapy within 3 postoperative days

Interventions

  • DrugL-arginine

    Initiation of L-arginine within 3 postoperative days

06

What researchers measure

Primary outcomes

  1. Acute kidney injury

    defined by KDIGO criteria

    Time frame: within 7 postoperative days

Secondary outcomes

  1. 7-day mortality.

    7-day mortality.

    Time frame: 7 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Lei C, Berra L, Rezoagli E, Yu B, Dong H, Yu S, Hou L, Chen M, Chen W, Wang H, Zheng Q, Shen J, Jin Z, Chen T, Zhao R, Christie E, Sabbisetti VS, Nordio F, Bonventre JV, Xiong L, Zapol WM. Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery. Am J Respir Crit Care Med. 2018 Nov 15;198(10):1279-1287. doi: 10.1164/rccm.201710-2150OC. PubMed 29932345 ↗
  • Landoni G, Monaco F, Ti LK, Baiardo Redaelli M, Bradic N, Comis M, Kotani Y, Brambillasca C, Garofalo E, Scandroglio AM, Viscido C, Paternoster G, Franco A, Porta S, Ferrod F, Calabro MG, Pisano A, Vendramin I, Barucco G, Federici F, Severi L, Belletti A, Cortegiani A, Bruni A, Galbiati C, Covino A, Baryshnikova E, Giardina G, Venditto M, Kroeller D, Nakhnoukh C, Mantovani L, Silvetti S, Licheri M, Guarracino F, Lobreglio R, Di Prima AL, Fresilli S, Labanca R, Mucchetti M, Lembo R, Losiggio R, Bove T, Ranucci M, Fominskiy E, Longhini F, Zangrillo A, Bellomo R; PROTECTION Study Group. A Randomized Trial of Intravenous Amino Acids for Kidney Protection. N Engl J Med. 2024 Aug 22;391(8):687-698. doi: 10.1056/NEJMoa2403769. Epub 2024 Jun 12. PubMed 38865168 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07718373
Lead sponsor
Xijing Hospital
Responsible party
Chong Lei, MD & phD (Principal investigator, Head of Anesthesia Clinical Research Center, Xijing Hospital, Xijing Hospital) — Principal investigator
First posted
Jul 22, 2026
Start date
Jul 20, 2026 (estimated)
Primary completion
Aug 20, 2026 (estimated)
Completion
Aug 20, 2026 (estimated)
Last update
Aug 10, 2026

Study contacts

Zefei Zhang
Contact
zzfanita7@163.com
18811797795

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acute Kidney Injury→

Other studies from this sponsor

Xijing Hospital

Start the discussion